This would position Axiom as the first US biotech to pursue HKEX as a primary listing venue rather than Nasdaq or the NYSE. This is about building Axiom as a global company from the start and about opening a path that other American innovators can follow.” This collaboration reflects our shared commitment to bringing differentiated therapies to patients,” Iker Huerga, CEO of Pathos AI, said. As part of this effort, we have decided to acquire PolyPeptide, a global peptide CDMO,” a spokesperson for Samsung Biologics told BioXconomy. “Driven recently by treatments for obesity and diabetes, the demand for new peptide drugs is rising rapidly, and the peptide CDMO market continues to show robust growth.